Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.45%
#2 Venom Venom +23.49%
#3 Decred Decred +10.61%
#4 Wibx Wibx +8.05%
#5 Status Status +7.45%
#6 SkyAI SkyAI +7.31%
#7 aelf aelf +6.44%
#8 MarsCoin MarsCoin +5.78%
#9 Audiera Audiera +5.39%
#10 TRIA TRIA +4.71%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
Nanologica AB (publ) Nanologica AB (publ)

Nanologica AB (publ)

NICA
Rank in Stocks #30456
Nanologica AB (publ), a nanotechnology company, develops, manufactures, and... Nanologica AB (publ), a nanotechnology company, develops, manufactures, and sells nanoporous silica particles for life science industry in China, India, the United State of America, and internationally. It offers NLAB Saga, a new generation silica for preparative chromatography; and SVEA, a pre-packaged columns for analytical chromatography; and high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces. The company provides products for the analysis and purification of substances, with a focus on peptides drugs for the treatment of diabetes and obesity. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Share Price
$0.05093225
Last synced: 2026-08-18
Market Cap
$16.74M
Change (1 day)
1.11%
Change (1 year)
-68.04%
Country
SE
Trade Nanologica AB (publ) (NICA)

Category

Healthcare
P/E ratio for Nanologica AB (publ) (NICA)
P/E ratio as of 2026 TTM: 0
According to Nanologica AB (publ) latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nanologica AB (publ) from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 24.32 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.13 -
US
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.